Ibustrin, K 3920, is primarily used in the field of medical research and pharmacology due to its antiplatelet properties. It is studied for its potential to inhibit platelet aggregation, making it a candidate for the development of treatments aimed at preventing thrombosis in patients with cardiovascular diseases. Its application extends to clinical trials where it is evaluated for efficacy and safety in reducing the risk of heart attacks and strokes. Additionally, Ibustrin, K 3920, is explored for its possible use in conjunction with other therapeutic agents to enhance the management of blood clotting disorders. Researchers are also investigating its role in improving outcomes in surgeries where blood clot prevention is critical.